The question clinics ask about Chaeum Premium is not what hyaluronic acid filler does in general. It is much more specific: what is the real difference between No.1, No.2, No.3 and No.4, and which roles deserve a place on the treatment menu? The numbers are not a concentration ranking. Across lists No.1 at 24 mg/mL and the other three at 20 mg/mL, yet the family moves upward in documented G’, supplied needle gauge and injection depth.
Quick answer
Chaeum Premium No.1 is the line’s superficial detail option; No.2 is the flexible middle option spanning mid/deep dermis to subcutaneous placement; No.3 moves into a deeper volume-and-form role; and No.4 is the highest-G’ structural position in the range. Across’s current product page lists those injection depths, while an Across/Hugel brochure reports G’ values of 80 ± 15, 180 ± 15, 300 ± 15 and 400 ± 15 Pa from No.1 to No.4. All four contain 0.3% lidocaine and come as two 1.1 mL syringes per box. The useful clinic decision is therefore not “which number is best?” but “which treatment goals occur often enough to justify each 2.2 mL pack?”
What Chaeum Premium is designed to do
Hugel describes The Chaeum as a crosslinked HA filler line for the temporary improvement of adult facial wrinkles, and Across publishes four Premium variants with different product positions. The important distinction is the architecture of the family: one brand moves from a superficial, lower-G’ option to two progressively deeper and more elastic positions, then ends with a highest-G’ structural option.
That gives a clinic a clearer consultation story than “soft, medium, hard.” No.1 can be discussed as a detail role, No.2 as a bridge between detail and deeper shaping, No.3 as the volume-and-form step, and No.4 as the structural endpoint. These are Cytollia’s professional menu interpretations of the published specifications, not a good-better-best ranking.
Chaeum No.1–No.4 treatment goal and use map
The table combines three different evidence layers: Across’s current injection-depth and pack specifications, G’ values from the branded technical brochure, and that brochure’s high-level facial-position illustration. It is designed to help a trained clinic understand the range; it is not an injection technique.
| Variant | Documented G’ | Official injection depth | Professional treatment focus | Regions associated in the brochure | Needle and pack |
|---|---|---|---|---|---|
| Premium No.1 | 80 ± 15 Pa | Superficial dermis | Detail: fine, surface-level correction where a lower-elasticity role is preferred | Upper-face and perioral points, shown jointly with No.2 | 4 × 30G; 2 × 1.1 mL |
| Premium No.2 | 180 ± 15 Pa | Mid/deep dermis to subcutaneous | Balance: the broadest published depth range and a practical bridge between detail and shape | Upper-face and perioral points, shown jointly with No.1 | 4 × 27G; 2 × 1.1 mL |
| Premium No.3 | 300 ± 15 Pa | Deep subcutaneous | Volume and form: a deeper role with more documented elastic support than No.2 | Forehead and central-face/nasal points | 4 × 25G; 2 × 1.1 mL |
| Premium No.4 | 400 ± 15 Pa | Deep subcutaneous | Structure: the highest-G’ position for treatment goals requiring the strongest structural role in this family | Lower-face/chin point | 4 × 23G; 2 × 1.1 mL |
The brochure uses facial callouts rather than written area names, so the regional descriptions above stay deliberately broad. Product use, patient suitability and authorization vary by market and must follow the current local labeling and professional assessment.
No.1: the detail role
No.1 is the clearest proof that the numbering is not a simple strength score. It has the highest listed HA concentration at 24 mg/mL, but the lowest brochure G’ and the most superficial published injection depth. For a clinic, its value is not that it is “weaker”; it is that it gives fine-detail services a distinct place instead of asking a middle or structural product to cover every goal.
No.2: the flexible middle
No.2 has the widest depth statement on the current Across page, running from mid/deep dermis to subcutaneous placement. Combined with its second-step G’, that makes it the most obvious bridge product in the family. A clinic that does not yet need four Chaeum SKUs may find this middle role easier to justify than stocking two narrowly separated lower positions from day one.
No.3: deeper volume and form
No.3 moves the range to deep-subcutaneous placement and a brochure G’ of 300 ± 15 Pa. Its practical role is deeper volume and form without automatically jumping to the highest structural position. This is where the family begins to answer clinics that want a clearer step between an adaptable middle filler and the most structure-led option.
No.4: the structural endpoint
No.4 shares the deep-subcutaneous depth category with No.3 but sits higher in the brochure’s G’ ladder at 400 ± 15 Pa and is supplied with the largest-diameter needle in the range. Its role is structural projection and definition within the Chaeum menu. That does not make it the universal “best” Chaeum; it makes it the endpoint for a different treatment goal.
Why concentration alone gives the wrong answer
If HA concentration determined the hierarchy, No.1 would rank above No.2–No.4. The published product map shows the opposite: concentration drops after No.1 while G’, needle diameter and injection depth progress through the range. Concentration remains useful formulation information, but it cannot replace the combined decision of treatment goal, depth, gel behavior and patient anatomy.
How much weight should a clinic give the G’ numbers?
Use them as an internal map, not a universal league table. The 2018 Across/Hugel brochure reports 80, 180, 300 and 400 Pa under its stated brochure conditions. A 2019 peer-reviewed study that tested commercial fillers under one independent protocol measured approximately 76, 146, 232 and 340 Pa for the same four products. The absolute values changed, but the order remained the same. That is why G’ is useful for understanding this family while values from unrelated studies should not be compared as though every test condition were identical.
Brochure source note: DMR,TCU-BR180308ENG, created March 8, 2018, page 2; G’ values reproduced from the brochure’s product table. Independent test: Lee et al., Dermatologic Surgery, DOI 10.1097/DSS.0000000000001858.
Results and what clients can expect
Clients may see an immediate change in the treated contour or wrinkle, but the same-day appearance is not the settled result. Early swelling can temporarily make an area look fuller or less even, so a clinic should explain when review photographs and follow-up assessment will be meaningful.
The branded brochure reports that 91% of subjects in a 48-week comparative program showed wrinkle improvement at 24 weeks and 83% at 48 weeks. The brochure presents those figures jointly for Dermalax and The Chaeum, while the study citation names Dermalax Deep, so the useful takeaway is durability context rather than a promise that every Chaeum number lasts exactly one year. Across the broader HA filler literature, six to twelve months is a common planning range, with longevity affected by the product selected, treatment area, tissue movement, amount used, technique and individual metabolism.
Common reactions and practical precautions
Swelling, redness, tenderness, pain and bruising are common early filler reactions, and many settle within days to weeks. This should be part of the consultation because it changes how clients interpret the first mirror check and the first few photographs. Unusual or severe pain, white/grey/blue skin changes, visual symptoms or neurological symptoms require urgent medical assessment rather than routine aftercare. Chaeum Premium is a professional-use medical device, not a self-injection product.
Cytollia Clinic Fit
Strong fit
Clinics that want one teachable four-step family for detail, balance, volume and structure—and have enough recurring demand to use two syringes in every selected role.
Focused fit
Clinics that want Chaeum without carrying all four numbers. Start with the roles already represented in the treatment menu, then add a missing step when consultation and usage data justify it.
Potential mismatch
Low-volume clinics that prefer single-syringe trial purchasing may find the consistent two-syringe format creates more inventory per SKU than the current menu can absorb.
Treatment Menu Builder and Stocking Snapshot
A clinic does not need to present four syringe codes to clients. The customer chooses a treatment goal; the professional chooses the appropriate product after assessment. Behind the consultation, the numbered system can make training and reordering easier.
| Stocking model | Menu logic | Nominal volume committed | When it makes sense |
|---|---|---|---|
| One-role introduction | One Chaeum SKU tied to an established service | 2.2 mL in one box | The team wants to assess demand and handling before expanding the family. |
| Focused three-role range | Detail or balance + volume + structure | 6.6 mL across three boxes | The clinic needs broad coverage but does not yet have a business case for both lower positions. |
| Complete four-role range | Detail + balance + volume + structure | 8.8 mL across four boxes | All four treatment roles already produce repeatable demand. |
If fine-detail services are a regular category, No.1 earns a distinct slot. If the immediate need is a flexible middle position, No.2 may be the more practical first step. Add No.3 when deeper volume-and-form work is recurring, and add No.4 when the clinic has reliable demand for the family’s highest-G’ structural role. Reorder by actual role utilization, not by the desire to keep a visually complete shelf.
Chaeum Premium specifications at a glance
| Product family | The Chaeum Premium No.1, No.2, No.3 and No.4 |
|---|---|
| Manufacturer / brand relationship | Across product information; Hugel lists Across as an affiliate and The Chaeum as a Hugel brand |
| Product type | Crosslinked hyaluronic acid filler for temporary facial wrinkle improvement |
| HA concentration | No.1: 24 mg/mL; No.2–No.4: 20 mg/mL |
| Lidocaine | 0.3% in all four Premium variants |
| Syringe format | 2 × 1.1 mL per box |
| Supplied needles | No.1: 30G; No.2: 27G; No.3: 25G; No.4: 23G; four needles per box |
| Storage / shelf life | 2–25°C; 24 months on the current Across product page |
Frequently asked questions
What is Chaeum Premium used for?
Hugel describes The Chaeum as a crosslinked HA filler for temporary improvement of adult facial wrinkles. The four Premium numbers give clinics different positions for detail, balance, deeper volume and structure.
What treatment areas are associated with each Chaeum number?
The branded brochure groups No.1 and No.2 with upper-face and perioral points, No.3 with forehead and central-face/nasal points, and No.4 with a lower-face/chin point. These are broad brochure associations; the exact product, patient, current labeling and professional assessment determine suitability.
How long may Chaeum results last?
There is no single verified duration for every number and every treatment. Six to twelve months is a common planning range in broader HA filler literature, while product choice, area, tissue movement, amount, technique and metabolism can shorten or extend the visible result.
What reactions are common after treatment?
Temporary swelling, redness, bruising, tenderness and pain are common early reactions. Clinics should explain expected settling and the symptoms that require urgent medical assessment before treatment.
Does every Chaeum Premium box contain two syringes?
Across currently lists two 1.1 mL syringes for each of the four Premium variants covered here, together with four supplied needles. Confirm the exact delivered box when receiving stock.
Does a clinic need all four variants?
No. A full range makes sense only when all four roles generate repeat demand. A focused clinic can start with one or three roles and add the missing step when service and inventory data show a real need.
Choose the Chaeum roles that match your clinic
Compare the currently listed Chaeum Premium products, live availability and tier pricing against the services your clinic already sells. Start with the treatment goal, then decide which numbered role deserves inventory.
Related dermal filler product guides
- Dermalax Plus, Deep Plus and Implant Plus Clinic Guide
- Elravie Premier Light, Deep Line and Ultra Volume Clinic Guide
- Dermal Filler Clinic-Ready Product Guide
Sources and commercial disclosure
- Across: The Chaeum official product information
- Hugel: The Chaeum brand, indication and manufacturing overview
- Across/Hugel: Dermalax and The Chaeum technical brochure, DMR,TCU-BR180308ENG
- Lee et al.: Practical Guidelines for Hyaluronic Acid Soft-Tissue Filler Use in Facial Rejuvenation
- Xie et al.: Long-term safety and biodegradability of HA dermal fillers
- U.S. FDA: Dermal filler risks and patient information
Last verified: July 21, 2026. Cytollia sells the product family linked in this guide. Cytollia’s treatment-role and stocking analysis is editorial guidance for professional product research; live price and availability remain on the product page.